RE:RE:RE:RE:Bayer looking for a "mid-size M&A transaction" in oncologyAnd then there is Bayer's Chief Scientific Officer in oncology Christine Roth comment that conservatively $5 billion to $10 billion would be a good value estimate for a midsize M&A transaction.